Eroxon

Business

Futura Medical's Patent Win Extends US Market Protection for Eroxon and Pipeline Women's Health Product to 2040

UK-based Futura Medical secures a key US patent allowance, safeguarding its erectile dysfunction gel Eroxon and an investigational women's sexual health treatment until 2040, while triggering a $2.5 million milestone payment from partner Haleon.

Business

Futura Medical Raises Revenue Outlook Amid Strategic Review, Bolstered by Eroxon Momentum

UK-based Futura Medical has upgraded its full-year revenue forecast to £1.7 million for 2025, citing strong performance of its over-the-counter erectile dysfunction gel Eroxon. The announcement comes as the company prepares for a strategic review and anticipates key financial catalysts, including a milestone payment from partner Haleon.

Business

Futura Medical Shares Surge on Upbeat Revenue Outlook and Strong Cash Position

Shares in Futura Medical PLC jumped as much as 10% after the company upgraded its 2025 revenue forecast to £1.7 million and reported a robust year-end cash balance, extending its financial runway into late 2026.